Moyamoya Syndrome, Epilepsy and Hydrocephalus in Neurofibromatosis Type 1
International Journal of Developmental Neuroscience · 2025-08 · 85 (5)
DOI: 10.1002/jdn.70038 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Developmental Neuroscience, online erschienen am 04.08.2025. Verfasst von Fen Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Children's Hospital Affiliated to Shandong University/Jinan Children's Hospital, Jinan, China. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Moyamoya Disease, Epilepsy, Hydrocephalus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous syndrome. NF1‐related vasculopathy represents a clinically significant yet underrecognized complication. Moyamoya syndrome, a rare cerebrovascular manifestation of NF1, has been rarely reported in the paediatric population. Epilepsy and hydrocephalus are also uncommon neurological manifestations of NF1. However, the co‐occurrence of the above three symptoms in NF1 cases is rarely found.
Methods
Here, we report a 2‐year‐old boy with moyamoya syndrome, epilepsy and hydrocephalus caused by de novo NF1 pathogenetic variants.
Results
He experienced a 1‐week history of paroxysmal hands weakness and frequent seizures. Physical examination showed macrocephaly (head circumference was 52 cm), reduced distal muscle strength in both upper limbs (grade III) and the presence of 6 or more café‐au‐lait macules (CALMs). Brain magnetic resonance imaging (MRI) showed moyamoya syndrome and hydrocephalus. Electroencephalographic (EEG) monitored two episodes of electrical persistent seizures and one focal motor seizure. Trio whole exome sequencing (Trio‐WES) demonstrated a de novo and heterozygous NF1 missense mutation (c.5488C > G, p. Arg1830Gly). The final diagnoses were ‘neurofibromatosis type 1, moyamoya syndrome, epilepsy, and hydrocephalus’. Following surgical intervention and treatment with levetiracetam, the patient achieved normal muscle strength and was seizure‐free.
Conclusion
When articles about complications of NF1 are placed in a separate category, little is written about NF‐1‐related moyamoya syndrome, hydrocephalus and epilepsy simultaneously. This report describes a case of NF1 with moyamoya syndrome combined with hydrocephalus and epilepsy, which could enhance clinicians' understanding of the neurological manifestations of NF1 and provide reference value for clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Children's Hospital Affiliated to Shandong University/Jinan Children's Hospital, Jinan, China.
- Department of Neurosurgery, Children's Hospital Affiliated to Shandong University/Jinan Children's Hospital, Jinan, China.
ORCID-Profile: Fen Zhao
Zitieren
APA
Zhao, F., Yue, X., Wang, G., & Zhang, H. (2025). Moyamoya Syndrome, Epilepsy and Hydrocephalus in Neurofibromatosis Type 1. International Journal of Developmental Neuroscience, 85(5). https://doi.org/10.1002/jdn.70038
Vancouver
Zhao F, Yue X, Wang G, Zhang H. Moyamoya Syndrome, Epilepsy and Hydrocephalus in Neurofibromatosis Type 1. International Journal of Developmental Neuroscience. 2025;85(5). doi:10.1002/jdn.70038
BibTeX
@article{Zhao2025,
author = {Zhao, Fen and Yue, Xizan and Wang, Guangyu and Zhang, Hongwei},
title = {Moyamoya Syndrome, Epilepsy and Hydrocephalus in Neurofibromatosis Type 1},
journal = {International Journal of Developmental Neuroscience},
year = {2025},
volume = {85},
number = {5},
doi = {10.1002/jdn.70038}
}
EUVIMED